Skip to main content
N4 PHARMA PLC logo

N4 PHARMA PLC — Investor Relations & Filings

Ticker · N4P ISIN · GB00BYW8QM32 LEI · 213800I841D2RKMFK955 IL Professional, scientific and technical activities
Open in API
Filings indexed 840 across all filing types
Latest filing 2020-01-29 Regulatory Filings
Country GB United Kingdom
Listing IL N4P

About N4 PHARMA PLC

https://n4pharma.com/

N4 Pharma PLC is a specialist pharmaceutical company focused on the development of Nuvec®, its proprietary silica nanoparticle delivery system. This platform technology is designed to enhance the cellular delivery and potency of nucleic acid-based treatments, such as vaccines and cancer therapies. The company's primary focus is on applying Nuvec® to enable advanced therapies for oncology and infectious diseases. N4 Pharma's business model involves developing and out-licensing its technology to pharmaceutical and biotechnology partners to improve the performance of new and existing drugs.

Recent filings

Filing Released Lang Actions
Update on Nuvec® process improvements
Regulatory Filings Classification · 1% confidence The document is identified by the 'RNS Number' header and explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' RNS stands for Regulatory News Service, which is a general regulatory announcement mechanism, often used for updates that don't fit a more specific SEC filing category (like 10-K or ER). The content is an operational update regarding product development ('Update on Nuvec® process improvements') rather than a formal financial report, management change, or dividend announcement. Since it is a general regulatory announcement from the London Stock Exchange's news service and doesn't fit precisely into the other specific categories (like MANG, DIV, ER, etc.), the most appropriate classification is the general regulatory filing category.
2020-01-29 English
Verona Pharma to Present at LSX World Congress 2020
Regulatory Filings Classification · 1% confidence The document is a press release dated January 28, 2020, announcing that the CFO of Verona Pharma will present at the LSX World Congress on February 4-5, 2020. This announcement concerns a corporate event where management will present an overview, which aligns with materials shared during investor conferences or meetings. This is not a formal regulatory filing like a 10-K or IR, nor is it a transcript (CT) or a formal earnings release (ER). It is an announcement about management presenting corporate information to investors, which fits best under Investor Presentation (IP) or potentially a general Regulatory Filing (RNS) if IP is too specific for an event announcement. However, since the content is about a corporate overview presentation at an investor event, 'Investor Presentation' (IP) is the most appropriate category, as it details management's plan to present company strategy and financials to investors, even if the presentation document itself is not attached here. Given the context of presenting corporate information at an investor conference, IP is the strongest fit over the general RNS.
2020-01-28 English
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is explicitly labeled with an 'RNS Number' and contains the header 'TR-1: Standard form for notification of major holdings'. This form is used to report changes in significant share ownership, which falls under regulatory disclosure requirements. The content details the acquisition/disposal of voting rights by a major shareholder (Richard Griffiths and controlled undertakings) in Evgen Pharma Plc, dated January 20, 2020. This type of mandatory regulatory filing, especially one identified by an RNS number and concerning shareholding changes, is best classified as a general Regulatory Filing (RNS), as there is a more specific category for 'Major Shareholding Notification' (MRQ). However, since TR-1 forms are standard regulatory disclosures often distributed via RNS, and the definition for RNS is 'General regulatory announcements and fallback category for miscellaneous filings that do not neatly fit into other specific categories,' RNS is appropriate. Given the specific nature of reporting major holdings, MRQ (Major Shareholding Notification) is the most precise fit among the provided options, as TR-1 notifications directly relate to crossing major shareholding thresholds.
2020-01-20 English
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is explicitly labeled with 'RNS Number : 2190A' and contains the standard format for a 'TR-1: Standard form for notification of major holdings'. This form is used to report changes in significant share ownership, which directly corresponds to the definition of Major Shareholding Notification (MRQ). Although RNS is mentioned as the source, the content itself is a specific regulatory filing type (TR-1) detailing a change in holding percentage, making MRQ the most accurate classification over the general RNS fallback.
2020-01-17 English
Holding(s) in Company TR-1: Standard form for notification of major holdings
Major Shareholding Notification Classification · 1% confidence The document is explicitly titled 'TR-1: Standard form for notification of major holdings' and contains structured tables detailing changes in voting rights percentages, share classes (ISINs), and the identity of the notifying shareholder (Arix Bioscience plc). This format is characteristic of regulatory filings related to significant changes in share ownership thresholds. This directly corresponds to the definition of Major Shareholding Notification (MRQ).
2020-01-17 English
Second Price Monitoring Extn
Regulatory Filings Classification · 1% confidence The document is very short (1501 characters) and contains the header 'RNS Number : 6550Z'. The content describes a 'Second Price Monitoring Extension' related to trading activity, which is a specific, immediate operational announcement concerning the stock exchange mechanism. This type of brief, operational regulatory update that doesn't fit into standard financial reporting categories (like 10-K, ER, or IR) is best classified under the general regulatory announcement category, RNS, as it is explicitly sourced from RNS and relates to market operations.
2020-01-13 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.